Maeda K - Search Results

1

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.

Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: maeda k. N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.

2

Identification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replication.

Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H. Miyakawa T, et al. Among authors: maeda k. J Biol Chem. 2002 Feb 15;277(7):4649-55. doi: 10.1074/jbc.M109198200. Epub 2001 Dec 4. J Biol Chem. 2002. PMID: 11734558 Free article.

3

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.

Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T, Mitsuya H. Maeda K, et al. Curr Opin Pharmacol. 2004 Oct;4(5):447-52. doi: 10.1016/j.coph.2004.07.004. Curr Opin Pharmacol. 2004. PMID: 15351348 Review.

4

Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.

Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H. Nakata H, et al. Among authors: maeda k. J Virol. 2005 Feb;79(4):2087-96. doi: 10.1128/JVI.79.4.2087-2096.2005. J Virol. 2005. PMID: 15681411 Free PMC article.

5

Development of therapeutics for AIDS: structure-based molecular targeting.

Maeda K, Mitsuya H. Maeda K, et al. Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S31-4. doi: 10.1016/j.tube.2007.05.009. Epub 2007 Jul 10. Tuberculosis (Edinb). 2007. PMID: 17625972 Review.

6

Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.

Mitsuya H, Maeda K, Das D, Ghosh AK. Mitsuya H, et al. Among authors: maeda k. Adv Pharmacol. 2008;56:169-97. doi: 10.1016/S1054-3589(07)56006-0. Adv Pharmacol. 2008. PMID: 18086412 Review. No abstract available.

7

[Structure-guided molecular-targeting approach for development of AIDS therapeutics].

Maeda K, Mitsuya H. Maeda K, et al. Nihon Rinsho. 2010 Oct;68(10):1889-95. Nihon Rinsho. 2010. PMID: 20954335 Review. Japanese.

8

CCR5 inhibitors: emergence, success, and challenges.

Maeda K, Das D, Nakata H, Mitsuya H. Maeda K, et al. Expert Opin Emerg Drugs. 2012 Jun;17(2):135-45. doi: 10.1517/14728214.2012.673584. Epub 2012 Apr 25. Expert Opin Emerg Drugs. 2012. PMID: 22533737 Review.

9

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.

Yasutake Y, Hattori SI, Hayashi H, Matsuda K, Tamura N, Kohgo S, Maeda K, Mitsuya H. Yasutake Y, et al. Among authors: maeda k. Sci Rep. 2018 Jan 26;8(1):1624. doi: 10.1038/s41598-018-19602-9. Sci Rep. 2018. PMID: 29374261 Free PMC article.

10

The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

Takamatsu Y, Das D, Kohgo S, Hayashi H, Delino NS, Sarafianos SG, Mitsuya H, Maeda K. Takamatsu Y, et al. Among authors: maeda k. Cell Chem Biol. 2018 Oct 18;25(10):1268-1278.e3. doi: 10.1016/j.chembiol.2018.07.014. Epub 2018 Aug 30. Cell Chem Biol. 2018. PMID: 30174310 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,816 results

Search Page